2704617-96-7
Chemical Structure
CFT8634
- CAS No.: 2704617-96-7
- Formula:C37H45F3N6O5
- Molecular Weight:710.79
IUPAC Name: (R)-2,3-bis((tetradecanoyl-d27)oxy)propyl (2-(tris(methyl-d3)ammonio)ethyl) phosphate
InChIKey: GNRGNRCQXHMQQV-ZQAZVOLISA-N
SMILES: CC(C(C1=CC(OC)=C(C(OC)=C1)CN2CC(F)([C@@H](N3CCN(C4=C(C=C(C=C4)N[C@@H]5C(NC(CC5)=O)=O)F)CC3)CC2)F)=CN6C)=C(C)C6=O
Biological Activity: CFT8634 is an orally active BRD9 PROTAC degrader with a DC50 of 0.003 μM (HEK293T.166). CFT8634 recruits the CRBN E3 ubiquitin ligase to form a ternary complex, triggering CRBN-catalyzed BRD9 polyubiquitination and 26S proteasome-mediated degradation. CFT8634 induces sustained tumor regression and inhibits tumor growth in mouse models. CFT8634 can be used in research related to synovial sarcoma, SMARCB-1-deficient cancers, acute myeloid leukemia, malignant rhabdoid tumors, and multiple myeloma[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
CFT8634 | 98.10% | CFT8634 is an orally active BRD9 PROTAC degrader with a DC50 of 0.003 μM (HEK293T.166). CFT8634 recruits the CRBN E3 ubiquitin ligase to form a ternary complex, triggering CRBN-catalyzed BRD9 polyubiquitination and 26S proteasome-mediated degradation. CFT8634 induces sustained tumor regression and inhibits tumor growth in mouse models. CFT8634 can be used in research related to synovial sarcoma, SMARCB-1-deficient cancers, acute myeloid leukemia, malignant rhabdoid tumors, and multiple myeloma. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Zeng S, et al. Current advances and development strategies of orally bioavailable PROTACs. European journal of medicinal chemistry. 2023 Dec 05;261:115793. [Content Brief]
- [2]. Jackson KL, et al. Discovery of CFT8634, a Potent, Selective, and Orally Bioavailable Heterobifunctional Degrader of BRD9. Journal of medicinal chemistry. 2025 Dec 11;68(23):24848-24868. [Content Brief]
- [3]. Christopher G. Nasveschuk, et al. Compounds for targeted degradation of brd9. WO2021178920A1. 2022-09-05.
